Announcements

Updates on campus events, policies, construction and more.

close  

Information for Our Community

Whether you are part of our community or are interested in joining us, we welcome you to WashU Medicine.

close  


Visit the News Hub

Study explains how ketogenic diets prevent seizures

New findings in mice shed light on brain’s response to the keto diet, long known to help treat some patients with epilepsy

by Mark ReynoldsFebruary 25, 2026

Keto foods in outline of brainSara Moser/WashU Medicine

A ketogenic diet — one that is high in fat and extremely low in carbohydrates — has been known for decades to reduce seizures in some epilepsy patients. But how the highly restrictive diet achieves these effects has not previously been understood.

Researchers at Washington University School of Medicine in St. Louis have now shown in mice that the diet causes physical changes in brain cells affecting how they send information to one another, dampening the strength of the signals between them. This quieter neural landscape might explain how the diet calms the overactive electrical signaling that characterizes an epileptic seizure.

The study appears this month in Cell Reports.

Ghazaleh Ashrafi, PhD, an associate professor in the WashU Medicine Department of Cell Biology & Physiology who led the study, said that the findings point to possible new ways of treating epilepsy.

“By better understanding how the diet works, it provides new avenues to develop interventions that are not as strict as the diet itself but still control seizures,” Ashrafi said.

Changing the brain by changing its fuel

A very strict version of the ketogenic diet has typically been used in children with epilepsy whose seizures do not respond to standard medications. In most of these patients, 90% of the patient’s daily calories must come from high-fat sources for the diet to work. With strict adherence, a ketogenic diet has been shown to reduce seizures by approximately 50% in some patients.

The high-fat, carbohydrate-restricted diet causes the liver to generate chemical compounds called ketones. Neurons in the brain metabolize ketones as fuel in the absence of glucose from carbohydrates, which would normally be their energy source. Ashrafi explained that although the ketogenic diet is effective at reducing seizures in epileptic patients, most people are unable to maintain compliance with the extremely strict diet, and even a slight deviation from the regimen eliminates its benefits.

While it was generally accepted that the switch to ketones as neuronal fuel was behind the anti-seizure effect, what specifically was happening in the brain was not known. Ashrafi and her colleagues sought to identify the specific changes in neurons triggered by the ketones as a way to find new targets for effective anti-seizure therapies that could be less burdensome for patients than wholesale diet changes.

Studying mice that had been restricted to a diet of high-fat pellets, Ashrafi and co-senior authors Gabor Egervari, MD, PhD, an assistant professor of genetics and biochemistry, and Vitaly A. Klyachko, PhD, a professor of cell biology and physiology, both at WashU Medicine, looked for changes in genetic activity in the hippocampus, the part of the brain where seizures commonly originate. They found hundreds of alterations, many of which were associated with genes connected to the functioning of synapses, the tips of brain cells that send messages to each other.

Having narrowed the scale of their search, the researchers then measured how the behavior of the synapses had changed in mice on the keto diet. They found that excitatory signals — the neurotransmitter chemicals telling neighboring neurons to activate — were lowered, while inhibitory chemicals that reduce neuronal responsiveness had increased. The overall effect was to dampen the strength of communication within brain-cell circuits, an effect that Ashrafi said would explain how the seizure-causing hyperactivity in cells characteristic of epilepsy can be mitigated by these diets.

Using a high-powered microscope, the team also found that neurons from mice on the ketogenic diet had fewer vesicles containing excitatory chemical signals than did mice on a normal mouse diet. Vesicles are tiny packets in brain cells that release the neurotransmitter signals that are received by neighboring cells. Ashrafi said the finding was consistent with the changes in gene activity the team had also identified.

She noted that the study points to the precise cellular changes needed to produce the anti-seizure effects of a ketogenic diet. Reproducing these effects with, say, medications or other interventions could offer potential new approaches to treating epilepsy.

“There are many intersections of diet and disease that could lead us to potential treatment strategies if we knew more about them,” said Ashrafi. “In this case, if we can mimic the molecular changes that are causing neurons to make fewer of these vesicles, we can mimic the anti-seizure effect without needing to profoundly change a patient’s diet.”

Stunault MI, Deng P-Y, Yadav A, Periandri EM, de Luna Vitorino FN, Michael B. Thomsen MB, Sponagel J, Barfield AJ, Ponce RJ, Foroughi L, Garcia BA, Egervari G, Klyachko VA, Ashrafi G. Ketogenic diet dampens excitatory neurotransmission by shrinking synaptic vesicle pools. Cell Reports. February 24, 2026. DOI: 10.1016/j.celrep.2026.116945

This work was supported by a McDonnell Center for Systems Neuroscience Small Grant, the Diabetes Research Center Pilot & Feasibility Award funded by the National Institute of Diabetes and Digestive and Kidney Problems grant P30 DK020579, National Institute for General Medical Science R35GM147222, the Whitehall Foundation, the Chan-Zuckerberg Initiative Early Acceleration Award, National Institutes of Health (NIH) R00AA028577, NARSAD Young Investigator grant YIG31527, NIH grants 7R01AI118891 and R01HD106051, and National Institute of Neurological Disorders and Stroke R35 NS111596. This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

About WashU Medicine

WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with more than 3,000 faculty. Its National Institutes of Health (NIH) research funding portfolio is the second largest among U.S. medical schools and has grown 83% since 2016. Together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently among the top five in the country, with more than 2,000 faculty physicians practicing at 130 locations. WashU Medicine physicians exclusively staff Barnes-Jewish and St. Louis Children’s hospitals — the academic hospitals of BJC HealthCare — and Siteman Cancer Center, a partnership between BJC HealthCare and WashU Medicine and the only National Cancer Institute-designated comprehensive cancer center in Missouri. WashU Medicine physicians also treat patients at BJC’s community hospitals in our region. With a storied history in MD/PhD training, WashU Medicine recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

Mark covers surgery, cell biology and physiology, radiology, neuroscience, neurosurgery, and both occupational and physical therapy. Prior to joining Washington University, he was a freelance writer for many years, specializing in science and medicine with publications in CNRS International, Canadian Geographic and the Medical Post, among others. He is a former editor of McGill University’s Headway/En Tête research magazine and has won awards from the Canada Council for the Advancement of Education including for best science writing. He has a bachelor’s degree from Dalhousie University in Halifax, Nova Scotia.